The abstract is read at the publisher; the summary is JClub's.
In adults with ESBL-producing Escherichia coli or Klebsiella pneumoniae bacteremia, serum albumin level does not significantly modify 30-day mortality by carbapenem group (P = .92).
- Why it matters: Guidelines prefer group 2 carbapenems over ertapenem for hypoalbuminemia, but clinical data showing whether albumin changes outcomes by carbapenem type are limited.
- What they did: In a multicenter retrospective cohort (3 hospitals; 2013–2020), adults received exclusively group 1 or group 2 carbapenems; inverse probability of treatment weighting balanced baseline factors, and weighted Cox/logistic models tested albumin-by-group interaction.
- The result: No significant interaction was found for 30-day mortality (P = .92) or 14-day mortality (P = .36), implying ertapenem efficacy is comparable to group 2 across observed albumin levels.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.